Published by Josh White on 25th July 2024
(Sharecast News) - AstraZeneca revised its full-year 2024 guidance upwards on Thursday, anticipating mid-teens percentage growth in both total revenue and core earnings per share at constant exchange rates.
URL: http://www.digitallook.com/dl/news/story/34449652/...